Department of Analytical Chemistry, Faculty of Pharmacy, Zagazig University, Egypt.
Aga Health Insurance Hospital, Dakahlia, Egypt.
Spectrochim Acta A Mol Biomol Spectrosc. 2018 Sep 5;202:159-173. doi: 10.1016/j.saa.2018.05.041. Epub 2018 May 26.
In accordance with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines, six novel, simple and precise sequential spectrophotometric methods were developed and validated for the simultaneous analysis of Ribavirin (RIB), Sofosbuvir (SOF), and Daclatasvir (DAC) in their mixture without prior separation steps. These drugs are described as co-administered for treatment of Hepatitis C virus (HCV). HCV is the cause of hepatitis C and some cancers such as liver cancer (hepatocellular carcinoma) and lymphomas in humans. These techniques consisted of several sequential steps using zero, ratio and/or derivative spectra. DAC was first determined through direct spectrophotometry at 313.7 nm without any interference of the other two drugs while RIB and SOF can be determined after ratio subtraction through five methods; Ratio difference spectrophotometric method, successive derivative ratio method, constant center, isoabsorptive method at 238.8 nm, and mean centering of the ratio spectra (MCR) at 224 nm and 258 nm for RIB and SOF, respectively. The calibration curve is linear over the concentration ranges of (6-42), (10-70) and (4-16) μg/mL for RIB, SOF, and DAC, respectively. This method was successfully applied to commercial pharmaceutical preparation of the drugs, spiked human urine, and spiked human plasma. The above methods are very simple methods that were developed for the simultaneous determination of binary and ternary mixtures and so enhance signal-to-noise ratio. The method has been successfully applied to the simultaneous analysis of RIB, SOF, and DAC in laboratory prepared mixtures. The obtained results are statistically compared with those obtained by the official or reported methods, showing no significant difference with respect to accuracy and precision at p = 0.05.
根据国际人用药品注册技术协调会(ICH)指导原则,开发并验证了 6 种新颖、简单、精确的顺序分光光度法,用于利巴韦林(RIB)、索非布韦(SOF)和达卡他韦(DAC)混合物的同时分析,无需预先进行分离步骤。这些药物被描述为联合用于治疗丙型肝炎病毒(HCV)。丙型肝炎病毒是导致丙型肝炎的原因,在人类中还会导致一些癌症,如肝癌(肝细胞癌)和淋巴瘤。这些技术包括几个顺序步骤,使用零、比值和/或导数光谱。DAC 首先通过直接分光光度法在 313.7nm 处测定,不受其他两种药物的干扰,而 RIB 和 SOF 可以通过五种方法在比值扣除后测定;比值差分光光度法、连续导数比值法、常数中心、238.8nm 等吸光度法和 224nm 和 258nm 处的比值光谱均值中心化(MCR)法,分别用于 RIB 和 SOF。RIB、SOF 和 DAC 的校准曲线在(6-42)、(10-70)和(4-16)μg/mL 的浓度范围内呈线性。该方法成功应用于药物的商业制剂、加标人尿和加标人血浆。上述方法是为同时测定二元和三元混合物而开发的非常简单的方法,可以提高信噪比。该方法已成功应用于实验室制备混合物中 RIB、SOF 和 DAC 的同时分析。所得结果与官方或报道方法的结果进行统计学比较,在 p=0.05 时,在准确度和精密度方面无显著差异。